Plain-English translation of NCT07493668 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new oral medication designed to work specifically in liver tissue, combined with (a drug already used for advanced liver cancer) helps patients whose disease has stopped responding to immunotherapy. The study compares this two-drug combination against alone to see which approach works better and is safer.
Many patients with advanced liver cancer do not respond well enough to first-line immunotherapy treatments, and their cancer continues to grow. Doctors need better second-line treatment options, and this medication appears to work through a different mechanism that could complement 's effects.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the combination group, you would take by mouth once daily for 5 days, followed by a 16-day rest period, repeating this 21-day cycle. You would also take daily without interruption (12 mg or 8 mg depending on your weight). If assigned to the -only group, you would take that medication continuously every day. You'll have regular clinic visits for blood tests, imaging scans, and check-ins to monitor how the treatment is working and any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
South Korea